ASBP Aspire Biopharma Holdings, Inc.
Healthcare$5.07-6.28%ClosedMarket Cap: $584,936
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.22
P/S
18.06
EV/EBITDA
1.44
DCF Value
$-0.51
FCF Yield
-995.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
16.3%
Operating Margin
-15745.9%
Net Margin
-34039.7%
ROE
199.4%
ROA
-165.3%
ROIC
-121.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $28.4K | 20.3% | $-1.6M | $-3.2M | $— | — |
| Q4 null | $4.3K | -23.5% | $-1.8M | $-4.7M | $— | — |
| FY null | $6.2K | -1.9% | $-19.4M | $-24.5M | $— | — |
| Q3 null | $1.9K | 45.5% | $-1.1M | $-1.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-799.9K | $-2.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.6M | $-15.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-640.5K | $-8.9M | $— | — |
| FY null | $0.00 | NaN% | $-3.1M | $-12.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-215.3K | $-537.0K | $— | — |
| Q2 null | $0.00 | NaN% | $-501.0K | $-602.0K | $— | — |
| Q1 null | $0.00 | NaN% | $-2.5M | $-2.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-403.0K | $-151.0K | $-0.00 | — |